BIO-TECHNE Corp (NASDAQ:TECH) has received an average rating of “Hold” from the nine ratings firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $198.50.
Several equities analysts have commented on the company. Janney Montgomery Scott raised BIO-TECHNE from a “neutral” rating to a “buy” rating and raised their price objective for the company from $200.00 to $270.00 in a research report on Tuesday, July 2nd. ValuEngine lowered BIO-TECHNE from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 1st. Zacks Investment Research lowered BIO-TECHNE from a “buy” rating to a “sell” rating in a research report on Tuesday, August 13th. BidaskClub lowered BIO-TECHNE from a “buy” rating to a “hold” rating in a research report on Saturday, July 13th. Finally, TheStreet lowered BIO-TECHNE from a “b” rating to a “c+” rating in a research report on Tuesday, August 6th.
In other news, SVP Brenda S. Furlow sold 5,400 shares of BIO-TECHNE stock in a transaction dated Friday, May 24th. The stock was sold at an average price of $200.00, for a total value of $1,080,000.00. Following the completion of the transaction, the senior vice president now owns 7,589 shares of the company’s stock, valued at approximately $1,517,800. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Robert V. Baumgartner purchased 500 shares of the stock in a transaction dated Wednesday, August 7th. The stock was bought at an average cost of $191.06 per share, with a total value of $95,530.00. Following the transaction, the director now owns 8,726 shares in the company, valued at $1,667,189.56. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 46,548 shares of company stock valued at $9,790,896. 3.80% of the stock is owned by insiders.
BIO-TECHNE stock traded up $1.27 on Friday, hitting $193.86. 1,722 shares of the stock traded hands, compared to its average volume of 175,824. The company has a current ratio of 4.05, a quick ratio of 3.15 and a debt-to-equity ratio of 0.42. The firm has a market cap of $7.48 billion, a P/E ratio of 50.92, a price-to-earnings-growth ratio of 4.24 and a beta of 1.17. The business’s fifty day simple moving average is $206.06 and its 200 day simple moving average is $199.75. BIO-TECHNE has a 1 year low of $132.75 and a 1 year high of $217.15.
BIO-TECHNE (NASDAQ:TECH) last announced its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.25 EPS for the quarter, beating the consensus estimate of $1.17 by $0.08. The business had revenue of $191.66 million during the quarter, compared to analyst estimates of $196.37 million. BIO-TECHNE had a return on equity of 13.20% and a net margin of 13.45%. The company’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same quarter last year, the firm posted $1.34 earnings per share. As a group, analysts predict that BIO-TECHNE will post 4.24 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, August 30th. Stockholders of record on Friday, August 16th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.66%. The ex-dividend date of this dividend is Thursday, August 15th. BIO-TECHNE’s dividend payout ratio is presently 33.68%.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents.
Recommended Story: What is a death cross?
Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.